title: Development of a Sol Particle Homogeneous Immunoassay for Measuring Full-Length Selenoprotein P in Human Serum.
abstract: BACKGROUND
  Selenoprotein P (SeP), a selenium-rich extracellular glycoprotein, is the primary selenoprotein in the plasma. SeP plays an important role in the maintenance of selenium levels in the peripheral tissues. We developed a new sol particle homogeneous immunoassay (SPIA) for measuring full-length SeP (FL-SeP) levels in the human serum.
  
  
  METHODS
  We used colloidal gold particles coated with two types of anti-SeP monoclonal antibodies, one recognizing the N-terminal side domain of SeP and the other recognizing the C-terminal side domain.
  
  
  RESULTS
  The assay range was 0.2-9 mg/l, and the linearity was excellent. The within-day and between-day coefficients of variation ranged from 0.73% to 2.24% and 0.45% to 1.11%, respectively. Serum samples (n = 200) were examined using the newly developed assay system (employing a Model 7070 Hitachi automatic clinical analyzer) and the conventional enzyme-linked immunosorbent assay. These two methods were compared using the Passing-Bablok regression analysis; the resulting regression equation and correlation coefficient were y = 0.940x + 0.165 and r = 0.954, respectively.
  
  
  CONCLUSIONS
  Our new SPIA assay is a fully automated homogeneous immunoassay that can be used in conjunction with various commercial analyzers. The assay was sensitive, precise, and suitable for clinical measurement of the FL-SeP in the human serum.
authors.affiliation: Diagnostic R&D, Development & Production Headquarters, Alfresa Pharma Corporation, Ibaraki City, Osaka, Japan.
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Tanaka
authors.affiliation: Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto, Japan.
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Saito
authors.affiliation: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Misu
authors.affiliation: Diagnostic R&D, Development & Production Headquarters, Alfresa Pharma Corporation, Ibaraki City, Osaka, Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Kato
authors.affiliation: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kita
authors.affiliation: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
authors.forename: Yumie
authors.initials: Y
authors.lastname: Takeshita
authors.affiliation: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
authors.forename: Takehiro
authors.initials: T
authors.lastname: Kanamori
authors.affiliation: Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Nagano
authors.affiliation: Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan.
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Nakagen
authors.affiliation: Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Urabe
authors.affiliation: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
authors.forename: Toshinari
authors.initials: T
authors.lastname: Takamura
authors.affiliation: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kaneko
authors.affiliation: Department of Nutritional Biochemistry, Hokkaido Pharmaceutical University, Otaru, Hokkaido, Japan.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Takahashi
authors.affiliation: Diagnostic R&D, Development & Production Headquarters, Alfresa Pharma Corporation, Ibaraki City, Osaka, Japan.
authors.forename: Naoto
authors.initials: N
authors.lastname: Matsuyama
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology; D002138:Calibration; D004797:Enzyme-Linked Immunosorbent Assay; D017979:Gold Colloid; D006384:Hemagglutination; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007610:Kallikreins / Q000097:blood; D057230:Limit of Detection; D059748:Proteolysis; D051149:Selenoprotein P / Q000097:blood*
chemical_list: D000925:Anticoagulants; D017979:Gold Colloid; D051149:Selenoprotein P; D007610:Kallikreins
keywords: colloidal gold; diabetes; homogeneous immunoassay; metformin; selenoprotein P